BCA
KRON

Berman Capital Advisors’s Kronos Bio KRON Stock Holding History

Berman Capital Advisors’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$6K Buy
+300
New +$6.44K ﹤0.01% 1380

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Berman Capital Advisors's KRON Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Kronos Bio (KRON) in Q3 2021: 300 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #1380 among its holdings.

83 funds tracked by Wall St. Rank hold KRON as of Q3 2021.

  • Berman Capital Advisors held 300 shares of Kronos Bio worth $6K as of Q3 2021.
  • Kronos Bio was a new Berman Capital Advisors position in Q3 2021.
  • Kronos Bio made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1380 holding.
  • 83 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.